Health In Tech earnings release, August 13, 2026

Health In Tech, Inc. (HIT) · Form 8-K, Item 2.02 · Filed · SEC filing

Health

In Tech Reports Second Quarter 2026 Financial Results

Contracted

Revenue of $32.3 Million as of June 30, 2026

Pipeline

Revenue of $66.3 Million as of July 31, 2026

Distribution

Partners Grew 19.9% Year Over Year

Stuart,

FL., August 13, 2026 /PRNewswire/ — Health In Tech, Inc. (Nasdaq: HIT) (“Health In Tech” or the “Company”), an AI-enabled InsurTech platform company, today announced its unaudited financial results for the three and six months ended June 30,

2026.

Second

Quarter and First-Half 2026 Highlights

2026

Outlook and Beyond

As of July 31, 2026, the Company had approximately $66.3 million in Pipeline Revenue, of which $1.9 million was contracted, while the remaining

$64.4 million is in the quoting or binding stage. Based on the Company’s estimated conversion rate of 15% to 40%, the Pipeline

Revenue in the quoting or binding stage is expected to generate approximately $9.7 million to $25.8 million of additional Contracted

Revenue. Under U.S. GAAP revenue recognition, this is expected to result in approximately $3.1 million to $8.3 million of GAAP revenue recognized in 2026, with an additional $6.6 million to $17.5 million of GAAP revenue expected to be recognized in 2027.

With five more months remaining in 2026, the Company expects to continue expanding its Pipeline Revenue through new product launches and new system enhancement. Supported by its growing base of Contracted Revenue, increasing forward revenue visibility, and continued pipeline development, the Company is reaffirming its full-year 2026 revenue guidance of $45 million to $50 million.

CEO

Commentary

Tim

Johnson, Chief Executive Officer of Health In Tech, commented, “We continued to execute against our long-term growth strategy during the quarter by investing in sales, marketing, and key talent, supported in part by the capital raised through our recent PIPE financing.

These investments are designed to expand our distribution network, accelerate product innovation, and strengthen our execution capabilities.

Our contracted book of business continued to grow, providing greater visibility into future revenue. We believe Contracted Revenue and

Pipeline Revenue are meaningful operating metrics that complement our GAAP financial results by illustrating the strength of our sales pipeline, the pace of customer conversion, and our expected revenue trajectory.”

Mr.

Johnson continued, “We also made meaningful progress on several strategic initiatives that we believe position the Company for its next phase of growth. During the quarter, we contractually secured our first employer group for the Three-Year Rate Stabilization

Program, a differentiated solution designed to provide employers with greater predictability in stop-loss pricing over a multi-year period.

This represents an important milestone as we advance toward the program’s anticipated launch in the capital markets. In parallel, we are engaged with several high-profile governmental organizations that are evaluating participation in the program, and we expect to provide additional updates in the coming months.

As we execute on our strategic roadmap, we remain on track to launch

HitRix, our next-generation marketplace platform, in the second half of 2026. While our current eDIYBS platform has transformed AI-enabled underwriting through bindable stop-loss quoting and customized plan design, HitRix expands the application of AI across the entire self-funded stop-loss insurance ecosystem. The platform leverages advanced AI-powered document intelligence to automate data extraction across multiple document types, enable intelligent plan comparisons, and facilitate an integrated competitive bidding process within a unified digital marketplace. By connecting a broad network of brokers, carriers, TPAs, and employer groups, HitRix is designed to increase market transparency, expand access to competitive stop-loss solutions, streamline the placement process, and deliver better outcomes for all participants across the self-funded insurance value chain.”

End

Notes²

Conference

Call Details

Health

In Tech will host a conference call to discuss its financial results for the second quarter of 2026 on August 13, 2026, at 5:00 p.m.

(ET). To participate in our live conference call and webcast, please dial 1-888-346-8982 or 1-412-902-4272 (for international participants).

A live audio webcast will be available via the Investor Relations page of Health In Tech’s website at https://healthintech.com/.

A replay of the webcast will be available for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

Non-GAAP

Financial Information

This release presents Adjusted EBITDA, a non-GAAP financial metric, which is provided as a complement to the results provided in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Management uses Adjusted EBITDA to provide investors with additional insight into operational performance and to facilitate comparison with other companies in the industry.

Adjusted EBITDA should not be considered an alternative to net income, operating income, or other GAAP measures. A reconciliation of historical non-GAAP financial information to the most directly comparable GAAP financial measure is provided in the accompanying tables found at the end of this release.³

Financial statements

Income Statement

Three Months Ended June 30, — (Unaudited)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
RevenuesRevenues from underwriting modeling (ICE)1,272,6472,090,5762,741,4614,442,560
RevenuesRevenues from fees (SMR)6,783,9737,223,27314,086,80512,886,273
RevenuesTotal revenues8,056,6209,313,84916,828,26617,328,833
RevenuesCost of revenues4,134,1273,003,9798,396,3745,663,564
RevenuesGross profit3,922,4936,309,8708,431,89211,665,269
Operating expensesSales and marketing expenses2,215,8891,226,7384,507,4902,316,993
Operating expensesGeneral and administrative expenses4,269,0943,775,4537,724,6527,022,218
Operating expensesResearch and development expenses875,811582,6091,796,2061,120,330
Operating expensesTotal operating expenses7,360,7945,584,80014,028,34810,459,541
Other income (expense):Interest income69,568108,198137,039193,564
Other income (expense):Other income100,000122,334118,399
Other income (expense):Other expense-52,341-52,341
Other income (expense):Total other income, net117,227108,198207,032311,963
Other income (expense):(Loss) income before income tax expense-3,321,074833,268-5,389,4241,517,691
Other income (expense):Income tax benefit (expense)809,888-202,6371,289,957-388,468
Other income (expense):Net (loss) income-2,511,186630,631-4,099,4671,129,223
Other income (expense):Net loss attributable to noncontrolling interests-162-162
Other income (expense):Net (loss) income attributable to common stockholders-2,511,024630,631-4,099,3051,129,223
Net (loss) income per shareBasic-0.040.01-0.070.02
Net (loss) income per shareDiluted-0.040.01-0.070.02
Weighted average common shares outstanding:Basic62,829,72555,382,39560,106,50255,003,233
Weighted average common shares outstanding:Diluted62,829,72555,632,35760,106,50257,004,070

Balance Sheet

December 31, — (Unaudited)

June 30, – 2026December 31, – 2025
Current assetsCash and cash equivalents6,514,8137,669,754
Current assetsAccounts receivable, net8,546,307756,288
Current assetsLoans receivable, net847,993815,995
Current assetsOther receivables, net3,392,0823,467,814
Current assetsDeferred offering costs102,586170,977
Current assetsPrepaid expenses and other current assets2,380,2843,280,148
Current assetsTotal current assets21,784,06516,160,976
Non-current assetsSoftware7,197,7186,530,894
Non-current assetsOperating lease - right-of-use assets104,277139,940
Non-current assetsLong-term prepaid expenses8,184258,151
Non-current assetsDeferred tax assets, net540,436
Non-current assetsTotal non-current assets7,850,6156,928,985
Non-current assetsTotal assets29,634,68023,089,961
Current liabilitiesAccounts payable and accrued expenses9,907,3704,188,811
Current liabilitiesOperating lease liabilities - current81,22576,195
Current liabilitiesOther current liabilities891,598
Current liabilitiesTotal current liabilities9,988,5955,156,604
Non-current liabilitiesDeferred tax liabilities757,675
Non-current liabilitiesOperating lease liabilities - non-current21,71363,617
Non-current liabilitiesTotal non-current liabilities21,713821,292
Non-current liabilitiesTotal liabilities10,010,3085,977,896
Stockholders’ equityCommon stock, $0.001 par value; Class A Common stock 150,000,000 shares authorized 53,858,083 and 46,006,000 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively53,85846,006
Stockholders’ equityCommon stock, $0.001 par value; Class B Common stock 50,000,000 shares authorized, 11,700,000 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively11,70011,700
Stockholders’ equityAdditional paid-in capital18,365,47311,834,121
Stockholders’ equityRetained earnings1,120,9335,220,238
Stockholders’ equityNoncontrolling interests72,408
Stockholders’ equityTotal stockholders’ equity19,624,37217,112,065
Stockholders’ equityTotal liabilities and stockholders’ equity29,634,68023,089,961

Cash Flow

Three Months Ended June 30, — (Unaudited)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Cash flows (used in) provided by operating activities:Net (loss) income-2,511,186630,631-4,099,4671,129,223
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:Bad debt (recovery) expense-2,9545,990-2,9545,990
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:Amortization expense320,320135,983723,787271,966
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:Provision for refund liability175,698108,402955,743
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:Provision for credit losses on other receivables739,773739,773
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:Deferred tax benefit-813,639-32,074-1,298,111-66,547
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:Interest income-15,999-15,999-31,998-31,998
Full release

Use of Forward-Looking Statements

Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities

Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about Health In Tech’s possible... (truncated)sition, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,”

“will,” “should,” “design,” “target,” “aim,” “hope,” “expect,”

“could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,”

“continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects

Health In Tech’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to Health In Tech’s operations, results of operations, growth strategy and liquidity.

About

Health In Tech

Health

In Tech, Inc. (Nasdaq: HIT) is an AI-enabled InsurTech platform company, which offers a marketplace that improves processes in the health insurance industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, Managing General Underwriter (“MGUs”) and third-party administrators (“TPAs”). Health In Tech’s platform serves as a marketplace for brokers, TPAs, MGUs and carriers to access self-funded health insurance for employers, providing functions including customized self-funded health plans, bindable stop-loss quotes, AI-enabled underwriting, claims administration and reporting integration.⁴

Health

In Tech, Inc.

Consolidated

Statements of Operations

(Unaudited)⁵

Reconciliation of Net (Loss) Income Attributable to Common Stockholders to Adjusted EBITDA

(Unaudited)⁶

Consolidated

Balance Sheets

(Unaudited)⁷

Consolidated

Statements of Cash Flows

(Unaudited)

Investor

Contact:

Health

In Tech Investor Relations ir@healthintech.com⁸

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Health In Tech earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.